JP2002501046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002501046A5 JP2002501046A5 JP2000528537A JP2000528537A JP2002501046A5 JP 2002501046 A5 JP2002501046 A5 JP 2002501046A5 JP 2000528537 A JP2000528537 A JP 2000528537A JP 2000528537 A JP2000528537 A JP 2000528537A JP 2002501046 A5 JP2002501046 A5 JP 2002501046A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- carboxamide
- trifluoromethyl
- azetidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 34
- -1 4- (trifluoromethyl) phenyl Chemical group 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801499.6A GB9801499D0 (en) | 1998-01-23 | 1998-01-23 | Chemical compounds iii |
| GB9801499.6 | 1998-01-23 | ||
| GB9824458.5 | 1998-11-06 | ||
| GBGB9824458.5A GB9824458D0 (en) | 1998-11-06 | 1998-11-06 | Chemical compounds II |
| PCT/GB1999/000223 WO1999037613A1 (en) | 1998-01-23 | 1999-01-22 | Azetidinecarboxamide derivatives for treating cns disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002501046A JP2002501046A (ja) | 2002-01-15 |
| JP2002501046A5 true JP2002501046A5 (https=) | 2006-02-23 |
| JP4542264B2 JP4542264B2 (ja) | 2010-09-08 |
Family
ID=26313009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000528537A Expired - Lifetime JP4542264B2 (ja) | 1998-01-23 | 1999-01-22 | Ｃｎｓ障害を処置するためのアゼチジンカルボキサミド誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6831078B1 (https=) |
| EP (1) | EP1049670B1 (https=) |
| JP (1) | JP4542264B2 (https=) |
| AT (1) | ATE220665T1 (https=) |
| AU (1) | AU2178099A (https=) |
| DE (1) | DE69902142T2 (https=) |
| DK (1) | DK1049670T3 (https=) |
| ES (1) | ES2181387T3 (https=) |
| PT (1) | PT1049670E (https=) |
| WO (1) | WO1999037613A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9917384D0 (en) * | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-III |
| CN102224135A (zh) * | 2008-11-24 | 2011-10-19 | Nsab神经研究瑞典公司分公司 | 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物 |
| CN115650893B (zh) * | 2022-10-24 | 2024-08-06 | 南通华祥医药科技有限公司 | 一种1-二苯甲基氮杂环丁烷-3-酮的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB872447A (en) * | 1958-12-23 | 1961-07-12 | Lepetit Spa | 1-carbamyl-3-substituted azetidines |
| US4226861A (en) | 1978-04-18 | 1980-10-07 | A. H. Robins Company, Inc. | N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides |
| IL68699A (en) | 1982-08-19 | 1986-08-31 | Robins Co Inc A H | 3-phenoxy-1-azetidine-carboxamides,their preparation and pharmaceutical compositions containing them |
| US4505907A (en) | 1982-09-02 | 1985-03-19 | A. H. Robins Company, Inc. | N-Formyl and N-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides |
| US4956359A (en) * | 1985-02-28 | 1990-09-11 | A. H. Robins Company, Inc. | 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics |
| IE58943B1 (en) | 1985-02-28 | 1993-12-01 | Robins Co Inc A H | 3-Aryloxy-azetidine-carboxamides |
-
1999
- 1999-01-22 AU AU21780/99A patent/AU2178099A/en not_active Abandoned
- 1999-01-22 DK DK99901781T patent/DK1049670T3/da active
- 1999-01-22 DE DE69902142T patent/DE69902142T2/de not_active Expired - Lifetime
- 1999-01-22 AT AT99901781T patent/ATE220665T1/de not_active IP Right Cessation
- 1999-01-22 WO PCT/GB1999/000223 patent/WO1999037613A1/en not_active Ceased
- 1999-01-22 PT PT99901781T patent/PT1049670E/pt unknown
- 1999-01-22 EP EP99901781A patent/EP1049670B1/en not_active Expired - Lifetime
- 1999-01-22 JP JP2000528537A patent/JP4542264B2/ja not_active Expired - Lifetime
- 1999-01-22 ES ES99901781T patent/ES2181387T3/es not_active Expired - Lifetime
- 1999-01-22 US US09/600,631 patent/US6831078B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2309953C2 (ru) | Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| JP2017528507A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| JP2004512328A5 (https=) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| RU98105169A (ru) | Производные 8-азабицикло[3.2.1]окт-2-ена, их получение и применение | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2002502432A (ja) | 呼吸機能低下およびミューオピオイド化合物の付随的副作用を低減するための組成物および方法 | |
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2002515435A (ja) | 鬱病処置のための組合せ治療 | |
| JP2008509187A5 (https=) | ||
| RU2012141951A (ru) | Курс лечения с использованием агониста рецептора sip | |
| JP2008110984A5 (https=) | ||
| RU2005137165A (ru) | Применение соединения для лечения нарушений сна | |
| JP2007507494A5 (https=) | ||
| JP2004504376A5 (https=) | ||
| BRPI0609952A2 (pt) | métodos para modular a função da bexiga | |
| JP2005508872A5 (https=) | ||
| JP2002508364A5 (https=) | ||
| JP2021504384A5 (https=) | ||
| JP2008535835A5 (https=) | ||
| US10682343B2 (en) | Snoring treatment | |
| JP2003012557A (ja) | 不安及びうつ病のための多剤併用治療 | |
| JP2013536206A5 (https=) |